{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:20:41Z","timestamp":1762899641740,"version":"3.40.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2019,1,11]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Treatment of hematological malignancies with conventional DNA-damaging drugs, such as chlorambucil (CLB), commonly results in p53-dependent chemo-resistance. Chromatin modifying agents, such as histone deacetylase inhibitors (HDACIs), sodium butyrate (NaBu) and trichostatin A (TSA), may reverse chemo-resistance by modulating the activity of chromatin remodeling enzymes and\/or genes that control cell proliferation, differentiation and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This study examined the potential use of HDACIs and CLB combination therapies in an in vitro chemo-resistant leukemia model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>The p53-null promyelocytic leukemia cell line, HL60, was used as an in vitro model of chemo-resistant leukemia. Drug cytotoxicity was determined by tetrazolium salt-based colorimetric assays and Annexin V\/propidium iodide staining (flow cytometry). The level of mRNA expression of the chromatin modifying genes was measured by quantitative real-time PCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Micromolar concentrations of CLB combined with either NaBu or TSA triggered synergistic cytotoxic effects in HL-60 cells (p &lt; 0.001). The effects of the combination treatments resulted in upregulated p21 gene expression (up to 59-fold; p&lt;0.001) that preceded an increase in BCL6 gene expression (up to 20-fold; p &lt; 0.001). Statistically significant but smaller magnitude changes (\u2264 2-fold; p &lt;0.05) were noted in the expression of other genes studied regardless of the treatment type.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The combination treatment of p53-null HL-60 cells with DNA-damaging agent CLB and HDACIs NaBu and TSA triggered additive to synergistic effects on apoptosis and upregulated BCL6 and p21 expression. These findings reveal BCL6 and p21 as potential targets of chemo-resistance for the development of anti-leukemic drugs.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874467211666181010161836","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T06:31:13Z","timestamp":1539585073000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression"],"prefix":"10.1016","volume":"12","author":[{"given":"Faith A.A.","family":"Kwa","sequence":"first","affiliation":[{"name":"School of Health and Biomedical Sciences, Royal Melbourne Institute of Technology University, Bundoora, Victoria 3083, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merrole F.","family":"Cole-Sinclair","sequence":"additional","affiliation":[{"name":"Haematology Department, St Vincent\u2019s Hospital, Fitzroy, Victoria 3065, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav K.","family":"Kapuscinski","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, Victoria 3053, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428190802688517","volume":"50","author":"Eichhorst B.","year":"2009","unstructured":"Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia.","journal-title":"Leuk Lymphoma"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"Hillmen P.","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, Doubek M, Panagiotidis P, Kimby E, Schuh A, Pettitt AR, Boyd T, Montillo M, Gupta I, Wright O, Dixon L, Carey JL, Chang C, Lisby S, McKeown A, Offner F. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial.","journal-title":"Lancet"},{"key":"ref=3","first-page":"368","volume":"2015","author":"Stilgenbauer S.","year":"2015","unstructured":"Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia.","journal-title":"Ash Educ Program Book"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"C373","DOI":"10.1152\/ajpcell.00325.2015","volume":"310","author":"Rigg R.A.","year":"2016","unstructured":"Rigg RA, Aslan JE, Healy LD, Wallisch M, Thierheimer ML, Loren CP, Pang J, Hinds MT, Gruber A, McCarty OJ. Oral administration of Bruton\u2019s tyrosine kinase inhibitors impairs GPVI-mediated platelet function.","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-010-1530-7","volume":"68","author":"Hebb J.","year":"2011","unstructured":"Hebb J, Assouline S, Rousseau C, DesJardins P, Caplan S, Egorin MJ, Amrein L, Aloyz R, Panasci L. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"39","author":"Hallek M.","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia.","journal-title":"The Lancet"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.mayocp.2018.03.002","volume":"93","author":"Strati P.","year":"2018","unstructured":"Strati P, Jain N, O\u2019Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment.","journal-title":"Mayo Clin Proc"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cdd.4401194","volume":"10","author":"Sturm I.","year":"2003","unstructured":"Sturm I, Bosanquet AG, Hermann S, G\u00fcner D, D\u00f6rken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.","journal-title":"Cell Death Differ"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.10226","volume":"98","author":"Bush J.A.","year":"2002","unstructured":"Bush JA, Li G. Cancer chemoresistance: The relationship between p53 and multidrug transporters.","journal-title":"Int J Cancer"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","volume":"84","author":"Wattel E.","year":"1994","unstructured":"Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.","journal-title":"Blood"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"Herman G.","year":"2003","unstructured":"Herman G, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation.","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood.V97.9.2784","volume":"97","author":"Carter B.Z.","year":"2001","unstructured":"Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia.","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2165\/11315680-000000000-00000","volume":"69","author":"Ma X.","year":"2009","unstructured":"Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: Current status and overview of recent clinical trials.","journal-title":"Drugs"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)00020-0","volume":"13","author":"Shaffer A.L.","year":"2000","unstructured":"Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.","journal-title":"Immunity"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ni1245","volume":"6","author":"Phan R.T.","year":"2005","unstructured":"Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal centre B cells.","journal-title":"Nat Immunol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1038\/sj.emboj.7600853","volume":"24","author":"Fujiki R.","year":"2005","unstructured":"Fujiki R, Kim M, Sasaki Y, Yoshimura K, Hirochika K, Kato S. Ligand-induced transrepression by VDR through association of WSTF with acetylated histones.","journal-title":"EMBO J"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.2008.07046.x","volume":"141","author":"Nahi H.","year":"2008","unstructured":"Nahi H, Selivanova G, Lehmann S, Mollgard L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.","journal-title":"Br J Haematol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biopha.2015.08.032","volume":"75","author":"Kachalaki S.","year":"2015","unstructured":"Kachalaki S, Baradaran B, Majidi J, Yousefi M, Shanehbandi D, Mohammadinejad S, Mansoori B. Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60).","journal-title":"Biomed Pharmacother"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0145-2126(98)00013-7","volume":"22","author":"Pepper C.","year":"1998","unstructured":"Pepper C, Thomas A, Tucker H. Flow cytometric assessment of three different methods for the measurement of apoptosis.","journal-title":"Leuk Res"},{"key":"ref=20","first-page":"2597","volume":"50","author":"Rieger A.M.","year":"2011","unstructured":"Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death.","journal-title":"J Vis Exp"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L","volume":"37","author":"Aubry J-P.","year":"1999","unstructured":"Aubry J-P, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, Moine V, Bonnefoy JY. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity.","journal-title":"Cytometry"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtbi.2014.04.032","volume":"357","author":"Jones L.B.","year":"2014","unstructured":"Jones LB, Secomb TW, Dewhirst MW, El-Kareh AW. The additive damage model: A mathematical model for cellular responses to drug combinations.","journal-title":"J Theor Biol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2144\/05385MT01","volume":"38","author":"Abruzzo L.V.","year":"2005","unstructured":"Abruzzo LV, Lee KY, Fuller A, Silverman A, Keating MJ, Coombes KR. Validation of oligonucleotide microarray data using microfluidic low-density arrays: A new statistical method to normalize real-time RT-PCR data.","journal-title":"Biotechniques"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbrc.2010.11.019","volume":"403","author":"Kwa F.A.","year":"2010","unstructured":"Kwa FA, Cole-Sinclair M, Kapuscinski M. Chlorambucil-sensitive and -resistant lymphoid cells display different responses to the histone deacetylase inhibitor, sodium butyrate.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/IAI.72.1.414-429.2004","volume":"72","author":"Mullick A.","year":"2004","unstructured":"Mullick A, Elias M, Harakidas P, Marcil A, Whiteway M, Ge B, Hudson TJ, Caron AW, Bourget L, Picard S, Jovcevski O, Massie B, Thomas DY. Gene Expression in HL60 Granulocytoids and Human Polymorphonuclear Leukocytes Exposed to Candida albicans.","journal-title":"Infect Immun"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"C373","DOI":"10.1152\/ajpcell.00325.2015","volume":"310","author":"Rigg R.A.","year":"2016","unstructured":"Rigg RA, Aslan JE, Healy LD, Wallisch M, Thierheimer MLD, Loren CP, Pang J, Hinds MT, Gruber A, McCarty OJT. Oral administration of Brutons tyrosine kinase inhibitors impairs GPVI-mediated platelet function.","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=27","first-page":"203","volume":"9","author":"Ahmadzadeh A.","year":"2015","unstructured":"Ahmadzadeh A, Khodadi E, Shahjahani M, Bertacchini J, Vosoughi T, Saki N. The Role of HDACs as Leukemia Therapy Targets using HDI.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"Mann B.S.","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.","journal-title":"Oncologist"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.drudis.2011.05.012","volume":"16","author":"Kwa F.A.","year":"2011","unstructured":"Kwa FA, Balcrczyk A, Licciardi P, El-Osta A, Karagiannis TC. Chromatin modifying agents - the cutting edge of anticancer therapy.","journal-title":"Drug Discov Today"},{"key":"ref=30","first-page":"3697","volume":"57","author":"Medina V.","year":"1997","unstructured":"Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin a (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial\/cytochrome c-dependent pathway.","journal-title":"Cancer Res"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s12094-015-1322-y","volume":"17","author":"Wei Z.","year":"2015","unstructured":"Wei Z, Gao W, Wu Y, Ni B, Tian Y. Mutual interaction between BCL6 and miRNAs contributing to the pathogenesis of various cancers.","journal-title":"Clin Transl Oncol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2008-07-168773","volume":"113","author":"Cerchietti L.C.","year":"2009","unstructured":"Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects and","journal-title":"Blood"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbrc.2009.11.078","volume":"39","author":"Choi J.H.","year":"2010","unstructured":"Choi JH, Min NY, Park J, Kim JH, Park SH, Ko YJ, Kang Y, Moon YJ, Rhee S, Ham SW, Park AJ, Lee KH. TSA-induced DNMT1 down-regulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4161\/cbt.2.3.364","volume":"2","author":"Parker B.S.","year":"2003","unstructured":"Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S. Mitoxantrone mediates demethylation and reexpression of Cyclin D2, estrogen receptor and 14.3.3 sigma in breast cancer cells.","journal-title":"Cancer Biol Ther"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jsbmb.2006.12.038","volume":"103","author":"Kato S.","year":"2007","unstructured":"Kato S, Fujiki R, Kim MS, Kitagawa H. Ligand-induced transrepressive function of VDR requires a chromatin remodelling complex, WINAC.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/jcb.21361","volume":"102","author":"Daniel C.","year":"2007","unstructured":"Daniel C, Schroder O, Zahn N, Gaschott T, Steinhilber D, Stein JM. The TGF beta\/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression.","journal-title":"J Cell Biochem"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1541-7786.MCR-06-0318","volume":"5","author":"Ting H.J.","year":"2007","unstructured":"Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1 alpha,25-dihydroxyvitamin D-3 responsiveness.","journal-title":"Mol Cancer Res"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jcp.21116","volume":"21","author":"Secchiero P.","year":"2007","unstructured":"Secchiero P, di Iasio MG, Gonelli A, Barbarotto E, Melloni E, Tiribelli M, Chiaruttini C, Zauli G. Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high low levels of zap-70.","journal-title":"J Cell Physiol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4174\/jkss.2009.77.5.297","volume":"77","author":"Park D.G.","year":"2009","unstructured":"Park DG. The changes of expression of survivin by butyrate in HCT116 colon cancer cells.","journal-title":"J Korean Surg Soc"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ijrobp.2006.06.049","volume":"66","author":"Sah N.K.","year":"2006","unstructured":"Sah NK, Munshi A, Hobbs M, Carter BZ, Andreeff M, Meyn RE. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.yexcr.2014.01.024","volume":"324","author":"Saldanha S.","year":"2014","unstructured":"Saldanha S, Kala R, Tollefsbol T. Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate.","journal-title":"Exp Cell Res"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"16790","DOI":"10.1074\/jbc.M110.216846","volume":"286","author":"Ge Z.","year":"2011","unstructured":"Ge Z, Wang H, Parthum MR, Hoffman CS, Annunziato AT. Nuclear Hat1p complex (NuB4) components participate in DNA repair-linked chromatin reassembly.","journal-title":"J Biol Chem"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"22045","DOI":"10.1074\/jbc.M201736200","volume":"277","author":"Lemercier C.","year":"2002","unstructured":"Lemercier C, Brocard M, Puvion-Dutilleul F, Kao H, Albagli O, Khochbin S. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor.","journal-title":"J Biol Chem"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0167-4889(01)00128-8","volume":"540","author":"Zhang H.","year":"2001","unstructured":"Zhang H, Okada S, Hatano M, Okabe S, Tokuhisa T. A new functional domain of BCL6 family that recruits histone deacetylases.","journal-title":"Biochim Biophys Acta"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10585-007-9131-5","volume":"25","author":"Mottet D.","year":"2008","unstructured":"Mottet D, Castronovo V. Histone deacetylases: Target enzymes for cancer therapy.","journal-title":"Clin Exp Metastasis"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"11294","DOI":"10.1073\/pnas.0903854106","volume":"106","author":"Saito M.","year":"2009","unstructured":"Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, Crespo M, Shen Q, Bhagat G, Califano A. BCL6 suppression of BCL2 Miz1 and its disruption in diffuse large B cell lymphoma.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","volume":"82","author":"Heider U.","year":"2009","unstructured":"Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I, Assaf C, Sezer O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteosome inhibitor bortezomib in cutaneous T cell lymphoma.","journal-title":"Eur J Haematol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.4049\/jimmunol.0803693","volume":"183","author":"Zhou J.X.","year":"2009","unstructured":"Zhou JX, Lee CH, Qi CF, Wang H, Naghashfar Z, Abbasi S, Morse III. IFN Regulatory Factor 8 regulates MDM2 in germinal center B cells.","journal-title":"J Immunol"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/166142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:56:40Z","timestamp":1746572200000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/166142\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467211666181010161836","relation":{},"ISSN":["1874-4672"],"issn-type":[{"type":"print","value":"1874-4672"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}